Androgen News and Research RSS Feed - Androgen News and Research

Novel way of hitting prostate cancer

Novel way of hitting prostate cancer

Researchers at UC Davis, in collaboration with the other institutions, have found that suppressing the nuclear receptor protein ROR-γ with small-molecule compounds can reduce androgen receptor (AR) levels in castration-resistant prostate cancer and stop tumor growth. [More]
FDA announces required class-wide safety labeling changes for IR opioid pain medications

FDA announces required class-wide safety labeling changes for IR opioid pain medications

In a continuing effort to educate prescribers and patients about the potential risks related to opioid use, the U.S. Food and Drug Administration today announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. [More]
Research uncovers biological differences between male, female breast cancers

Research uncovers biological differences between male, female breast cancers

Male breast cancer (Male BC) has important biological differences that distinguish it from female breast cancer, but to date these have been little studied and Male BC patients have been excluded from many clinical trials in breast cancer. [More]
Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by maintaining a population of chemo-sensitive cells. [More]
Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). [More]
Vanderbilt physicians examine risk factors for cardiovascular disease in prostate cancer survivors

Vanderbilt physicians examine risk factors for cardiovascular disease in prostate cancer survivors

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease's slow progression. [More]
Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others. [More]
Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology. [More]
Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing. [More]
Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Biocept introduces blood-based test for detection, monitoring of prostate cancer and breast cancer

Biocept, Inc., a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer. [More]
High diversity among circulating tumor cells predicts survival, treatment resistance in prostate cancer patients

High diversity among circulating tumor cells predicts survival, treatment resistance in prostate cancer patients

Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies. [More]
New discovery may soon make prostate cancer cells easier to destroy

New discovery may soon make prostate cancer cells easier to destroy

A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy. Drugs that could capitalize on the discovery are already in the pipeline, and a clinical trial to test whether the finding could improve treatments for prostate cancer patients could be only a few years away. [More]
High testosterone levels in women may increase uterine fibroid risk

High testosterone levels in women may increase uterine fibroid risk

Women who have high levels of both testosterone and estrogen in midlife may face a greater risk of developing benign tumors on the uterus called uterine fibroids than women with low levels of the hormones, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA reports net loss of $11.5 million for year ended September 30, 2015

ESSA Pharma Inc. today reported financial results for the year ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with International Financial Reporting Standards ("IFRS"). [More]
Androgen deprivation therapy elevates Alzheimer’s risk

Androgen deprivation therapy elevates Alzheimer’s risk

US researchers find that androgen deprivation therapy increases the risk of Alzheimer’s disease in men with prostate cancer, with the risk rising with greater duration of therapy. [More]
Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer's disease in the years that followed than those who didn't undergo the therapy, an analysis of medical records from two large hospital systems by Penn Medicine and Stanford University researchers has shown. [More]
Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium. [More]
Finding may lead to better understanding of male genital birth defects

Finding may lead to better understanding of male genital birth defects

University of Florida Health researchers have identified genes that are disrupted by abnormal hormone signaling at crucial points during development, a finding that may lead to a better understanding of how the most common male genital birth defects arise in humans. [More]
Men with prostate cancer get stronger bones from playing football

Men with prostate cancer get stronger bones from playing football

Men with prostate cancer run the risk of brittle bones as a side-effect of their treatment. But one hour's football training a few times a week counters many of the negative effects of the treatment, according to University of Copenhagen scientists. [More]
MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Researchers at the UC Davis Comprehensive Cancer Center have shown that the microRNA, miR-124, reduced tumor growth and increased cell death in castration-resistant prostate cancer. [More]
Advertisement
Advertisement